Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)

Market Cap	5.59B +14.2%
Revenue (ttm)	1.32B +4.3%
Net Income	386.02M +104.9%
EPS	1.50 +105.3%
Shares Out	256.15M
PE Ratio	14.54
Forward PE	n/a
Dividend	0.35 (1.61%)
Ex-Dividend Date	Apr 29, 2025

Volume	567,580
Average Volume	3,407,532
Open	21.79
Previous Close	21.84
Day's Range	21.75 - 21.97
52-Week Range	14.90 - 28.77
Beta	0.22
RSI	46.12
Earnings Date	Mar 25, 2026

About SHE:002393

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers its products in various forms comprising tablets, capsules, granules, and injections for use in various therapeutic fields, such as nervous system, musculoskeletal, genitourinary system, antineoplastic and immune system, sensory system, systemic anti-infection, respiratory system, endocrine system, digestive system, and cardiovascular system, as well as drugs for invigo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 1,604
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002393

Financial Performance

In 2024, SHE:002393's revenue was 1.34 billion, an increase of 15.88% compared to the previous year's 1.15 billion. Earnings were 184.53 million, a decrease of -49.00%.